Yazar "Berktas, Haci Bayram" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim Yok
    Öğe
    Effect of neuro-linguistic programming on COVID-19 fear in kidney transplant patients: A randomized controlled study
    (Elsevier Sci Ltd, 2022) Dogan, Aysel; Dogan, Runida; Menekli, Tugba; Berktas, Haci Bayram
    This study was conducted experimentally to evaluate the effect of neuro-linguistic programming (NLP) on fear of COVID-19 in kidney transplant patients. The study was carried out between June 2021 and October 2021. The Personal Information Form and COVID-19 Fear Scale (FCV-19S) were used to collect data. The obtained data obtained were evaluated using the SPSS 25 software. NLP was found to reduce the fear of COVID-19 in kidney transplant patients. Clinical nurses can use NLP techniques to support patients with fear in similar patient groups. Patients can be provided with access to training programs where they can learn NLP techniques. Clinicaltrials.gov: NCT05115435.
  • Küçük Resim
    Öğe
    Etodolac induced acute interstitial nephritis and autoimmune hemolytic anemia
    (2016) Berktas, Haci Bayram; Yiğit, İrem Pembegül; Taşkapan, Hülya; Akpolat, Nusret
    Abstract: In spite of the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs) such as etodolac, induction of drug-dependent antibodies that cause hemolytic anemia and acute tubulointerstitiel nephritis are rarely reported. Currently, there is no way of identifying individuals who are at risk to develop this kind of complications. In patients who present with acute immune hemolysis and acute renal failure, it is important that a careful history of medication be obtained, potential sensitizing medications be identified. In this article we describe a patient with acute autoimmune hem olytic anemia and acute renal failure related with etodolac
  • Küçük Resim Yok
    Öğe
    The evaluation and classification of drug-related problems by a clinical pharmacist in an internal diseases intensive care unit: A prospective cohort 7-month study
    (Istanbul Univ, Fac Pharmacy, 2024) Durmus, Mefkuere; Gun, Zeynep Ulku; Berktas, Haci Bayram
    Background and Aims: Drug -related problems can cause morbidity and mortality as well as increase health-care costs. Clinical pharmacists provide many benefits to healthcare systems by detecting, decreasing, and preventing drug -related problems. It was aimed to determine and classify drug -related problems and determine risk factors for drug -related problems. Methods: Drug -related problems were evaluated prospectively between August 16, 2021, and March 16, 2022, in 257 patients during their hospital stay who were hospitalized in the internal diseases intensive care unit and took at least one drug. Patients who were not administered any drug or who were younger than 18 were excluded from the study. The Pharmacetical Care Network Europe v.9 method was utilized to classify these problems. Clinical and demographic characteristics of patients with and without drug -related problems were compared by statistical analysis. Risk factors of drug -related problems were determined by logistic regression analysis. Results: At least one drug -related problem was detected in 157 of the 257 patients and a total of 399 drug -related problems were recorded. 399 recommendations were made, and 349 (87.5%) of these were accepted and 50 (12.5%) were not accepted. Drug selection (C1) was the most common cause of drug -related problems at 42.2%, and dose selection (C3) followed this by 41.5%. The results of regression analysis showed that atrial fibrillation (OR: 2.985, CI: 1.158-7.692), hematopoietic stem cell transplantation (OR: 3.883, CI: 1.256-11.999), antibacterial drugs (OR: 3.285, CI: 1.563-6.904), or polypharmacy (OR: 3.955, CI:1.207- 11.071) were risk factors of drug -related problems. Conclusion: The most common drug -related problem category was found as treatment safety and the causes of them were found as drug selection and dose selection. Clinicians should pay attention when prescribing new drugs to patients with atrial fibrillation and a history of hematopoietic stem cell transplantation. Furthermore, clinicians and clinical pharmacists should pay attention if polypharmacy and antibacterial drugs are present in medical therapies.
  • Küçük Resim Yok
    Öğe
    Hope or Hazard? The Safety Profile of Roxadustat in Patients With Anemia
    (Cig Media Group, Lp, 2025) Sarici, Ahmet; Berktas, Haci Bayram; Erkurt, Mehmet Ali; Tanriverdi, Lokman Hekim
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    A life-saving therapy in Class I HELLP syndrome: Therapeutic plasma exchange
    (Pergamon-Elsevier Science Ltd, 2015) Erkurt, Mehmet Ali; Berber, Ilhami; Berktas, Haci Bayram; Kuku, Irfan; Kaya, Emin; Koroglu, Mustafa; Nizam, Ilknur
    HELLP syndrome, which can affect multiple organ systems and cause maternal and fetal mortality, is a serious complication of pregnancy characterized by microangiopathic hemolytic anemia, elevation of liver enzymes, and thrombocytopenia. Delivering the infant usually suffices for the treatment of this syndrome. In cases with Class I HELLP syndrome, however, the clinical picture may rapidly deteriorate despite delivery. In this paper we presented the outcomes with the use of therapeutic plasma exchange in cases with class I HELLP syndrome. This study included 21 patients diagnosed with the Class I HELLP syndrome at Inonu University Faculty of Medicine, Department of Hematology between 2011 and 2014. A central venous catheter was placed and plasma exchange therapy was begun in patients unresponsive to delivery, steroid, and supportive therapy (blood and blood products, antihypertensive therapy, intravenous fluid administration, and antibiotics) within 24 hours after the diagnosis of Class I HELLP syndrome according to the Mississippi Criteria. All patients underwent therapeutic plasma exchange for three sessions each with a 1:1 volume. Hemogram and biochemical parameters of the patients were evaluated before and after the procedure. According to results, there was a statistically significant decrease in total bilirubin, LDH, AST, and ALT levels whereas a significant increase in platelet count was observed. Hemoglobin levels were increased, although this increase was not statistically significant. HELLP syndrome is primarily treated with the delivery of infant; however, some cases may show disease progression despite completion of delivery. As a potential cause of both maternal and fetal mortality, HELLP syndrome condition should be aggressively treated. Therapeutic plasma exchange is one of the available treatment options. Our study has found that postpartum use of plasma exchange therapy within 24 hours is an efficient and lifesaving treatment choice in Class I HELLP syndrome. (C) 2014 Elsevier Ltd. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Safety Profile of Roxadustat in Anemic Patients: A Meta-Analysis of 21 RCTs
    (Galenos Publ House, 2025) Tanriverdi, Lokman Hekim; Sarici, Ahmet; Erkurt, Mehmet Ali; Berktas, Haci Bayram
    Objective: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia in patients with chronic kidney disease. We aimed to assess its safety and tolerability profile through a meta-analysis of randomized controlled trials (RCTs). Methods: A systematic search of the Cochrane CENTRAL, Ovid Medline R, PubMed, and Web of Science databases was conducted up to January1, 2025 was conducted. RCTs comparing roxadustat with control groups were included. Inverse-variance-weighted random-effects models were used. The primary outcome was the risk of any serious treatment-emergent adverse event (TEAE). Subgroup analyses were based on etiology, comparator, and prior erythropoiesis-stimulating agent (ESA) use. Results: Twenty-one RCTs involving 11.686 patients were included. Roxadustat was not associated with a higher risk of any serious TEAE compared with placebo [risk ratio (RR) =1.37, 95% confidence interval (CI): 0.79-2.371 or with ESA (RR=1.05, 95% CI: 0.99-1.10). Similarly, cardiac serious adverse events (SAEs) did not differ significantly when compared with ESA (RR=1.11, 95% CI: 0.75-1.12) or placebo (RR=1.11, 95% CI: 0.92-1.35). Hyperkalemia incidence was significantly higher compared with placebo (RR=1.25, 95% CI: 1.02-1.53) but not compared with ESA (RR=1.03, 95% CI: 0.77-1.36). There were also no significant differences in the incidence of serious infections (RR=0.74, 95% CI: 0.21-2.59), azotemia (RR=0.96, 95% CI: 0.46-2.00), hypertension (RR=1.06, 95% CI: 0.93-1.21), or pneumonia (RR=0.96, 95% CI: 0.81-1.14) compared with ESA. Notably, withdrawal due to adverse events (RR=2.11, 95% CI: 1.59-2.79) was significantly higher compared with ESA. TEAEs leading to death were similar compared with ESA (RR=0.98, 95% CI: 0.85-1.13) but were increased compared with placebo (RR=1.21, 95% CI: 1.04-1.42). All-cause mortality was significantly lower than with placebo (RR=0.40, 95% CI: 0.28-0.57) but was similar to ESA (RR=0.89, 95% CI: 0.57-1.37). Subgroup analyses for the primary outcome by etiology and prior ESA use were not consistent with the main findings. Conclusions: Roxadustat demonstrated a SAE profile generally comparable to that of ESA, with no significant differences in cardiac SAEs, serious infections, azotemia, hypertension, or pneumonia. Hyperkalemia was more frequent compared with placebo, and withdrawals due to adverse events were more frequent compared with ESA. TEAEs leading
  • Küçük Resim Yok
    Öğe
    Sonoelastographic evaluation of diaphragmatic thickness and stiffness in dialysis patients
    (Bmc, 2025) Dag, Nurullah; Berktas, Haci Bayram; Uslu, Aysun Gunduz; Burulday, Veysel
    Objectives This study aimed to quantitatively and noninvasively assess diaphragmatic alterations in patients with end-stage renal disease undergoing hemodialysis (HD) or peritoneal dialysis (PD) using ultrasonography (US) and shear wave elastography (SWE). Methods This prospective cross-sectional study included 69 dialysis patients (HD, n = 37; PD, n = 32) and 60 demographically matched healthy controls. Right hemidiaphragm was evaluated using greyscale US and SWE through the 8th-10th intercostal spaces in the mid-axillary line. Thickness and stiffness were measured at end-expiration and peak inspiration phases. Clinical data, laboratory parameters, and dialysis-related metrics were recorded. Comparative and correlational analyses were performed using appropriate statistical methods. Results At peak inspiration, the measurements were 2.24 +/- 0.25 mm and 25.61 +/- 6.15 kPa for the HD group, 2.53 +/- 0.23 mm and 32.79 +/- 5.31 kPa for the PD group, and 2.86 +/- 0.29 mm and 47.68 +/- 6.67 kPa for the control group. Significant differences were observed between the groups for both parameters (p < 0.001). At end expiration, diaphragm thickness and stiffness were 1.69 +/- 0.20 mm/19.46 +/- 4.37 kPa, 1.75 +/- 0.19 mm/22.62 +/- 4.84 kPa, and 2.00 +/- 0.19 mm/33.26 +/- 4.62 kPa in the HD, PD, and control groups, respectively. There were significant differences between the groups (p < 0.05). ROC analysis indicated excellent diagnostic performance of these parameters for distinguishing dialysis patients from controls (AUC 0.806-0.987). Furthermore, diaphragm parameters correlated significantly with dialysis duration, adequacy, comorbidity, and serum albumin levels. Conclusion Diaphragm thickness and stiffness are reduced in dialysis patients, especially those on hemodialysis. US and SWE may serve as early imaging biomarkers for respiratory sarcopenia.